view4D pharma PLC

4D pharma says 2020 has been defining for live biotherapeutics field

4D pharma said it had built on its leading position in teh field over the year

4D pharma plc -

4D pharma plc (LON:DDDD) said 2020 has been a defining period for the rapidly developing field of live biotherapeutics in a statement alongside results for the half-year to end June.

In August, the AIM-listed group reported a phase I/II trial of its live biotherapeutic in combination with established cancer drug Keytruda had “far exceeded” the threshold for success set out before the study began.

4D’s MRx0518 has been developed to work synergistically with Keytruda to re-engage the immune system and stop the effects of the drug wearing off.

Axel Glasmacher, chair, added that 4D pharma had built on its leading position in the live biotherapeutics field over the year.

“We announced proof-of-concept efficacy data in oncology for lead candidate MRx0518, and have made meaningful progress in other important therapeutic areas. 

“In concert with this growth, 4D has further expanded both its leadership expertise and its international shareholder base.” 

4D pharma had cash and equivalents of £10mln at end June since when it had raised a further £7.7mln.

Losses for the half-year were £13.6mln after R&D spending of £12.4mln.

Quick facts: 4D pharma PLC

Price: 130.5 GBX

Market: LSE
Market Cap: £171.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...


2 min read